Cas:56396-10-2 (4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide manufacturer & supplier

Chemical Name:(4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide

CAS.NO:56396-10-2

Synonyms:EINECS 260-152-0;4-((5-(Anilino)carbonyl-2-methoxyphenyl)azo)-3-hydroxynaphthalene-2-carboxamide;Pigment Red 150;2-Naphthalenecarboxamide,3-hydroxy-4-(2-(2-methoxy-5-((phenylamino)carbonyl)phenyl)diazenyl);2-Naphthalenecarboxamide,3-hydroxy-4-((2-methoxy-5-((phenylamino)carbonyl)phenyl)azo)

Molecular Formula:C₂₅H₂₀N₄O₄

Molecular Weight:440.45100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.33

Index of Refraction:1.666

PSA:126.37000

Exact Mass:440.14800

LogP:6.09390

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like EINECS 260-152-0 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Naphthalenecarboxamide,3-hydroxy-4-((2-methoxy-5-((phenylamino)carbonyl)phenyl)azo) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pigment Red 150 Use and application,Pigment Red 150 technical grade,usp/ep/jp grade.

Related News: The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. (4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide manufacturer The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. (4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide supplier Some of Amanpour’s counterparts also offered well-wishes on Monday. (4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide vendor Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. (4Z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide factory The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.